PharmaShots | Incisive News in 3 Shots

Subscribe Now

Farxiga

AstraZeneca's Farxiga Receives the US FDA's Breakthrough Therapy Designation for Chronic Kidney Disease

AstraZeneca's Farxiga Receives the US FDA's Breakthrough Therapy Designation for Chronic Kidney Disease

October 5, 2020

AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-CKD Trial for Patients With and Without Type-2 Diabetes

AstraZeneca Reports Results of Farxiga (dapagliflozin) in P-III DAPA-CKD Trial for Patients With and Without Type-2 Diabetes

August 31, 2020

AstraZeneca Report Results of Farxiga in P-III DAPA-CKD Study for Patients with Chronic Kidney Disease

AstraZeneca Report Results of Farxiga in P-III DAPA-CKD Study for Patients with Chronic Kidney Disease

July 28, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us